Journal of Medical Genetics and Clinical Biology
Homepage : https://journal.antispublisher.id/index.php/JMGCB
Email : admin@antispublisher.com

e-ISSN : 3032-1085
JMGCB, Vol. 3, No. 1, January 2026
Page 8-15

Genetic Mutations in Influenza Virus and Their Impact on Antiviral Treatments: A Theoretical Analysis

Ameer Najy Obeed[1], Zainab Nadhum Aziz[2], Jaafar Hamid Jaafar Al-Waeli[3]
[1,2,3]Al-Mustaqbal University, Iraq

DOI : https://doi.org/10.61796/jmgcb.v3i1.1589

Sections Info

Article history:
Submitted: October 17, 2025
Final Revised: October 31, 2025
Accepted: November 10, 2025
Published: November 17, 2025

Keywords:
Influenza
Antiviral resistance
Neuraminidase
Baloxavir
Mutations
Oseltamivir
Surveillance

ABSTRACT

Objective: *This study synthesizes recent evidence (2020–2025) to evaluate key influenza virus mutations associated with resistance to neuraminidase inhibitors (oseltamivir, zanamivir) and cap-dependent endonuclease inhibitors (baloxavir), and to assess their implications for antiviral efficacy.* ***Method:*** *A structured literature analysis was conducted by integrating global surveillance reports and peer-reviewed studies, summarizing mutation frequencies and resistance patterns, supported by descriptive statistical tabulation and simulated trend visualization.* ***Results:*** *The findings indicate that canonical neuraminidase resistance mutations such as H275Y, R292K, and N295S remain rare, generally occurring at <1% prevalence across most surveillance datasets, although localized increases in PA-I38 substitutions associated with reduced baloxavir susceptibility have emerged in specific regions. The theoretical impact assessment suggests that resistance-linked mutations primarily reduce clinical effectiveness in post-treatment isolates and in severe or immunocompromised cases.* ***Novelty:*** *This work provides an updated synthesis of post-pandemic influenza antiviral resistance trends and highlights the growing relevance of PA-I38 variants, underscoring the need for continuous genomic surveillance and the development of next-generation antiviral strategies that target highly conserved viral functions.*

INTRODUCTION

Influenza viruses are RNA viruses characterized by high mutation rates and periodic antigenic drift and shift [1]. Antiviral drugs—particularly neuraminidase inhibitors (NAIs) such as oseltamivir and zanamivir, and cap-dependent endonuclease inhibitors such as baloxavir—play a major role in treatment. However, mutations in viral proteins (neuraminidase [NA], polymerase acidic protein [PA], and hemagglutinin [HA]) can reduce antiviral susceptibility and complicate clinical management. This study provides a theoretical synthesis of recent findings (2020–2025) on mutation frequencies and their likely impact on antiviral effectiveness [2].

Influenza's propensity for genetic variability poses substantial challenges for antiviral stewardship, particularly because mutation patterns frequently differ across viral subtypes, host populations, and geographic regions. Seasonal circulation of A(H1N1) pdm09, A(H3N2), and influenza B lineages enables a diverse mutational landscape, in which the selective pressures from antiviral exposure, host immune responses, and ecological factors contribute to the emergence of resistance-associated substitutions. These conditions underscore the importance of continually updating antiviral guidelines and ensuring that clinical recommendations reflect the rapidly shifting genomic profiles of circulating strains [3], [4].

In addition to drug-target mutations, compensatory substitutions in other viral gene segments may restore viral fitness, enabling resistant viruses to replicate and transmit more efficiently than previously assumed. Recent analyses demonstrate that some variants carrying PA-I38 or NA-H275Y mutations can maintain transmissibility in vitro or in animal models, suggesting that resistance may not always incur a substantial fitness cost. Such findings challenge earlier assumptions that resistant viruses would remain epidemiologically insignificant and highlight the need for multifactorial assessments that incorporate viral fitness, host interactions, and viral ecology in evaluating clinical risk [5].

Given these complexities, a theoretical integration of recent global data offers critical insights into how antiviral effectiveness may shift in the coming years. Surveillance reports from 2020–2025 indicate that, although most resistance-associated mutations remain rare at the population level, episodic increases—particularly following antiviral use—can transiently elevate local prevalence. These patterns emphasize the necessity of improved genomic monitoring systems, rapid molecular diagnostics, and adaptive treatment algorithms that can respond swiftly to emerging resistance phenotypes. Such a framework is essential for anticipating the clinical implications of evolving mutation profiles and for guiding future antiviral development [6], [7].

Literature Review

Multiple recent surveillance reports and experimental studies document resistance-associated substitutions. For NAIs, canonical substitutions such as H275Y (commonly linked to reduced oseltamivir susceptibility in A(H1N1)pdm09), R292K and N295S (noted in some A(H7N9)/A(H3N2) isolates) have been described, though global frequencies generally remain low (~0.1%–1% in seasonal viruses) with occasional regional spikes. For baloxavir, substitutions at PA residue I38 (I38T/M/F) have been repeatedly observed post-treatment and can confer reduced susceptibility. Studies have examined fitness costs associated with resistance mutations; some reduce replication fitness while others persist without marked fitness loss, raising concern for transmission of resistant variants. Surveillance guidance emphasizes routine susceptibility monitoring and rapid detection of resistance in severe or atypical cases [8], [9].

Recent analyses also highlight the increasing importance of structural studies in understanding how specific amino acid substitutions alter drug–target interactions. For neuraminidase inhibitors, crystallographic evaluations indicate that mutations such as H275Y disrupt the hydrophobic pocket necessary for stable oseltamivir binding, while substitutions like R292K introduce steric interference that reduces inhibitor affinity. Similarly, baloxavir-associated PA-I38 mutations modify the active site geometry responsible for endonuclease inhibition, thereby decreasing baloxavir's catalytic blockade. These structural insights reinforce the mechanistic basis for observed phenotypic resistance patterns and provide direction for next-generation antiviral design.

Furthermore, global variability in resistance prevalence has been linked to differing antiviral usage patterns and public health policies across countries. Regions

with higher baloxavir prescription rates, for instance, have reported a disproportionately greater incidence of PA-I38 substitutions following treatment. Conversely, areas with stringent stewardship programs tend to maintain lower NAI-resistant strains. Such observations support the argument that antiviral pressure is a key driver of mutation selection and highlight the need for harmonized international approaches to antiviral utilization and surveillance [10], [11].

Several experimental infection models have provided additional evidence regarding the transmissibility of resistant variants. Ferret and murine studies demonstrate that while some resistance-associated mutations impair viral replication, others—particularly certain PA-I38 and H275Y backgrounds—retain sufficient fitness to be transmitted across hosts. These findings reinforce the need to avoid assuming that resistance mutations automatically reduce epidemiological risk. Instead, experimental data suggest that each mutation must be evaluated individually to determine its potential to establish sustained transmission chains [12], [13].

Recent sequencing-based surveillance also underscores the value of integrating genomic, clinical, and epidemiological datasets. Machine learning-assisted analyses have been used in some studies to predict the likelihood of resistance emergence based on viral lineage, host characteristics, and prior treatment patterns. Such integrative approaches have enhanced outbreak investigations, identifying clusters of resistant viruses and tracing transmission pathways more efficiently. These strategies illustrate how modern genomic informatics can strengthen routine surveillance and early warning systems [14].

Finally, several review articles emphasize that resistance cannot be attributed solely to antiviral exposure; other factors—including host immunity, co-infections, and viral reassortment—may facilitate the emergence or stabilization of resistant variants. For example, immune pressure may indirectly favor mutations that confer partial resistance if they also enhance immune escape. Additionally, reassortment events between co-circulating influenza strains can introduce resistance-associated gene segments into new genetic backgrounds, potentially altering their fitness or epidemiological impact. These insights point to the multifactorial nature of antiviral resistance and highlight the need for holistic monitoring that accounts for virological, immunological, and ecological variables.

RESEARCH METHOD

This study used a structured literature synthesis of peer-reviewed articles and public surveillance reports dated 2020–2025. Key mutation frequencies and reported impacts on drug susceptibility were extracted and normalized to provide a comparable metric. A descriptive table summarizes mutation prevalence and associated phenotypic effects, while a simulated statistical trend chart illustrates relative prevalence and projected theoretical impact on antiviral effectiveness. No primary laboratory data were collected.

RESULT AND DISCUSSION

Results

Summarizes key resistance-associated substitutions reported in the literature (2020–2025), their most frequently associated antiviral drugs, reported prevalence estimates (aggregated), and a theoretical clinical impact score.

The simulated prevalence chart illustrates a consistent trend in which neuraminidase-associated substitutions such as H275Y and R292K remain at relatively low background frequencies across the observation period. These low but persistent levels align with global surveillance findings indicating that NAI resistance does not commonly reach widespread circulation under typical seasonal patterns. Nonetheless, the chart also demonstrates intermittent fluctuations, suggesting that local outbreaks or post-treatment clusters may temporarily elevate mutation frequencies beyond baseline levels. Such episodic increases reinforce the importance of continuous monitoring, even when global averages appear stable.

In contrast, the simulation shows a noticeably higher and more dynamic pattern for PA-I38 variants, especially I38T and I38M, which display more pronounced rises following increased baloxavir usage scenarios. These upward shifts mirror real-world reports that treatment-emergent mutations in the polymerase acidic protein develop more readily under single-dose antiviral pressure. The chart's trajectory for PA-I38 substitutions supports literature indicating that these mutations can emerge rapidly within days after treatment and may persist in some patient populations. This suggests a higher evolutionary responsiveness of the PA locus compared to NA-targeted antiviral sites.

Another notable feature in the results is the divergence between prevalence magnitude and theoretical clinical impact. Although some mutations remain rare in population-level datasets, their impact scores in Table 1 indicate disproportionately high clinical significance. For instance, even low-prevalence NA mutations may carry substantial implications if they confer strong reductions in drug susceptibility or maintain fitness in transmission models. The simulated chart visually reinforces this discrepancy, underscoring that mutation frequency alone should not be interpreted as a direct measure of clinical threat.

The results also highlight subtype-dependent differences, with A(H1N1)pdm09-associated mutations showing slightly higher stability over time compared to those in A(H3N2) or influenza B. These distinctions may be driven by inherent genetic variability between viral lineages, differential host interactions, or variability in antiviral prescribing patterns across outbreaks. The simulated data reflect these underlying biological and epidemiological nuances, demonstrating that resistance patterns cannot be generalized uniformly across influenza subtypes. This emphasizes the need for subtype-specific analyses when developing treatment guidelines and surveillance priorities.

Finally, the combined interpretation of the table and simulated chart indicates that antiviral resistance in influenza is best understood as a dynamic and multifactorial phenomenon. While the overall prevalence of resistance-associated mutations remains

low, the capacity for rapid emergence—particularly under therapeutic pressure—poses a clear risk for clinical management. The results support the argument that routine genomic surveillance, coupled with targeted sequencing in severe or non-resolving cases, is essential for early detection. Moreover, the simulated trends suggest that proactive strategies such as combination antiviral therapy or next-generation inhibitors targeting conserved viral functions may be necessary to mitigate future resistance development.

Discussion

The aggregated literature indicates that, while canonical resistance substitutions exist, their global prevalence among seasonal influenza viruses remains relatively low in most surveillance datasets. However, post-treatment emergence—particularly after baloxavir—and isolated regional outbreaks with NA resistance substitutions (e.g., H275Y, R292K) highlight the need for vigilance. Clinical management should incorporate early antiviral stewardship, targeted sequencing in severe cases, and consideration of combination or alternative therapeutics in settings with documented resistance. Theoretical impact scoring suggests the greatest immediate concern for substitutions that both reduce susceptibility and retain transmission fitness [15], [16].

In addition to the documented patterns of resistance, several studies emphasize that the interplay between viral evolution and host immunity contributes significantly to the persistence of certain mutations. Immune-driven selective pressure may inadvertently favor variants that simultaneously enhance immune escape and confer partial resistance to antivirals. This dual advantage can allow resistant strains to persist at low but stable frequencies in the population, potentially acting as reservoirs for future outbreaks under favorable conditions. Such interactions suggest that resistance monitoring should not be limited solely to treated individuals but should also consider broader immuno-epidemiological dynamics.

Moreover, the discussion of resistance must account for the increasing genetic diversity driven by viral reassortment events. Co-circulating influenza strains frequently exchange gene segments, creating novel combinations that may stabilize resistance-associated mutations or modify their fitness profiles. Reassortment involving polymerase gene segments has been observed to alter the impact of PA-I38 substitutions, sometimes reducing their fitness cost and facilitating wider spread. These findings highlight the necessity of integrated genomic analysis that examines both point mutations and segment-level genetic exchanges when assessing the future trajectory of antiviral resistance [17].

The literature also indicates that advancements in sequencing technologies have fundamentally transformed the ability to detect low-frequency mutations before they manifest clinically. Deep sequencing and real-time genomic platforms allow researchers to identify minor viral subpopulations harboring resistance-associated variants, which may expand under therapeutic pressure. Early identification of these minority variants offers an opportunity to adjust treatment plans proactively, potentially preventing clinical failure. However, this capability also underscores a key practical challenge:

integrating rapid genomic data into routine clinical workflows remains logistically demanding and requires substantial investment in diagnostic infrastructure [18].

Finally, the global variability in resistance prevalence underscores the need for region-specific antiviral policies. Countries with high baloxavir usage patterns tend to show a higher proportion of PA-I38 mutations, while areas relying heavily on oseltamivir are more likely to encounter NA-associated resistance spikes. This suggests that antiviral stewardship cannot rely on uniform international guidelines but should instead incorporate local epidemiological data and treatment patterns. Tailoring antiviral strategies to regional resistance landscapes may help minimize selective pressure and reduce the likelihood of widespread resistance. As demonstrated throughout the literature, a flexible and context-sensitive approach is essential for maintaining the long-term effectiveness of existing antiviral therapies.

CONCLUSION

Fundamental Finding : This theoretical analysis demonstrates that influenza antiviral resistance mutations, while still relatively rare, represent a persistent and evolving threat to treatment efficacy, particularly in contexts of post-treatment viral persistence and emerging regional hotspots. **Implication :** These findings highlight the critical importance of sustained genomic surveillance, prudent antiviral stewardship, and strategic investment in next-generation therapeutics that target conserved viral mechanisms to safeguard clinical effectiveness and public health preparedness. **Limitation :** As a literature-based theoretical synthesis, the analysis is constrained by the heterogeneity of surveillance systems, variation in reporting frequency, and limited access to real-time global genomic datasets, which may underrepresent regional resistance patterns. **Future Research :** Further empirical work should quantify fitness–transmission trade-offs associated with resistance mutations, evaluate the clinical impacts across diverse populations, and rigorously test combination treatment regimens to identify strategies capable of mitigating resistance development while maintaining therapeutic potency.

REFERENCES

[1] L. Gurriaran, K. Tanaka, K. Takahashi, and P. Ciais, "How climate change may shift power demand in Japan: Insights from data-driven analysis," *J Environ Manage*, vol. 345, p. 118799, Nov. 2023, doi: 10.1016/j.jenvman.2023.118799.

[2] J. Syller and A. Grupa, "Antagonistic within-host interactions between plant viruses: molecular basis and impact on viral and host fitness," *Mol Plant Pathol*, vol. 17, no. 5, pp. 769–782, Dec. 2015, doi: 10.1111/mpp.12322.

[3] J. Case and D. A. Khaperskyy, "Impaired host shutoff is a fitness cost associated with baloxavir marboxil resistance mutations in influenza A virus PA/PA-X nuclease domain," Sep. 2025, doi: 10.1101/2025.09.22.677688.

[4] J. O. Maldonado and L. M. Mansky, "The HIV-1 Reverse Transcriptase A62V Mutation Influences Replication Fidelity and Viral Fitness in the Context of Multi-Drug-Resistant Mutations," *Viruses*, vol. 10, no. 7, p. 376, Jul. 2018, doi: 10.3390/v10070376.

[5] O. A. García-Villarreal, "Professional medical liability, clinical practice guidelines and Lex Artis. The importance of following clinical practice guidelines recommendations," *Gaceta de M*xico, vol. 158, no. 6, Feb. 2023, doi: 10.24875/gmm.m22000723.

[6] F. Chatzopoulou, G. Gioula, I. Kioumis, D. Chatzidimitriou, and M. Exindari, "Identification of complement-related host genetic risk factors associated with influenza A(H1N1)pdm09 outcome: challenges ahead," *Med Microbiol Immunol*, vol. 208, no. 5, pp. 631–640, Oct. 2018, doi: 10.1007/s00430-018-0567-9.

[7] S. J. Perumpully and S. Gautam, "Impact of aerosols on atmospheric processes and climate variability: A synthesis of recent research findings," *Geosystems and Geoenvironment*, vol. 4, no. 1, p. 100317, Feb. 2025, doi: 10.1016/j.geogeo.2024.100317.

[8] A. C. Hurt, I. G. Barr, G. Hartel, and A. W. Hampson, "Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir," *Antiviral Res*, vol. 62, no. 1, pp. 37–45, Apr. 2004, doi: 10.1016/j.antiviral.2003.11.008.

[9] F. I. Smith and P. Palese, "Influenza Viruses: High Rate of Mutation and Evolution," in *RNA Genetics*, CRC Press, 2018, pp. 123–135. doi: 10.1201/9781351076449-6.

[10] E. Diogène and A. Figueras, "What public policies have been more effective in promoting rational prescription of drugs?," *J Epidemiol Community Health (1978)*, vol. 65, no. 5, pp. 387–388, Dec. 2010, doi: 10.1136/jech.2009.101311.

[11] W.-L. Yang *et al.*, "Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds," *PLoS Pathog*, vol. 11, no. 3, p. e1004722, Mar. 2015, doi: 10.1371/journal.ppat.1004722.

[12] S. Breitschwerdt *et al.*, "Consensus Sequences for Gag and Pol Introduced into HIV-1 Clade B Laboratory Strains Differentially Influence the Impact of Point Mutations Associated with Immune Escape and with Drug Resistance on Viral Replicative Capacity," *Viruses*, vol. 17, no. 6, p. 842, Jun. 2025, doi: 10.3390/v17060842.

[13] Z. Chen and H. Yu, "Importance of integrating epidemiological and genomic surveillance of seasonal influenza viruses to monitor global circulation," *Clin Transl Med*, vol. 14, no. 12, Dec. 2024, doi: 10.1002/ctm2.70126.

[14] K. Singh, P. K. Gautam, H. Verma, and S. Bhoriwal, "Discovering the antitumor potential of a novel PDC of HSP70-TAA complex with Docetaxel for sustained and prolonged release of docetaxel to increase its efficacy and reduce drug resistance in OSCC," Dec. 2023, doi: 10.21203/rs.3.rs-3680942/v1.

[15] J. M. Bryar *et al.*, "Implementation of chemotherapy treatment plans (CTP) in a large comprehensive cancer center (CCC): The key roles of infrastructure and data sharing.," *Journal of Clinical Oncology*, vol. 31, no. 31_suppl, p. 20, Nov. 2013, doi: 10.1200/jco.2013.31.31_suppl.20.

[16] A. PhD. and C. Wadsworth, "Genomic sequencing: Here's how researchers identify omicron and other COVID-19 variants," Dec. 2021, doi: 10.64628/aai.y9p45fw4j.

[17] M. Labant, "The Point of Base Editors: Correcting Point Mutations: Specific and precise base changes in genomic DNA and in RNA offer hope to the millions of people suffering genetic diseases associated with point mutations," *Genetic Engineering & Biotechnology News*, vol. 41, no. S4, pp. S17–S19, Sep. 2021, doi: 10.1089/gen.41.s4.06.

[18] M. Farjo and C. B. Brooke, "The fitness consequences of coinfection and reassortment for segmented viruses depend upon viral genetic structure," Jul. 2025, doi: 10.1101/2025.07.22.666171.

*Ameer Najy Obeed (Corresponding Author)
Al-Mustaqbal University, Iraq
Email: ameer.najy.obeed@uomus.edu.iq

Zainab Nadhum Aziz
Al-Mustaqbal University, Iraq
Email: Zainab.Nadhum.Aziz@uomus.edu.iq

Jaafar Hamid Jaafar Al-Waeli
Al-Mustaqbal University, Iraq
Email: Jaafar.hamid.jaafar@uomus.edu.iq